Levetiracetam Micro Labs

Levetiracetam, the active ingredient in Levetiracetam Micro Labs, is an anticonvulsant presented as an injectable solution for intravenous use. Approved in the European Union, it is employed to control partial, generalized tonic‑clonic and myoclonic seizures in patients with epilepsy, offering rapid plasma concentrations for acute seizure management.

GNH USA supplies Levetiracetam Micro Labs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable, quality‑assured products for acute care and chronic management, ensuring compliance with international regulatory standards and supporting global health initiatives.

Levetiracetam is an antiepileptic drug that modulates neuronal excitability to reduce seizure activity across several seizure types. - Partial seizures: reduces frequency and severity of focal onset seizures, improving daily functioning. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes in patients with generalized epilepsy, contributing to seizure freedom. - Myoclonic seizures: decreases occurrence of sudden muscle jerks associated with myoclonic epilepsy, aiding motor control. - Adjunctive therapy in refractory epilepsy: used alongside other antiepileptics when seizures are not controlled by monotherapy.

Levetiracetam may be associated with a range of adverse reactions, varying from mild and transient to severe and potentially life‑threatening. Common Side Effects: - Dizziness: transient feeling of light‑headedness or imbalance. - Somnolence: increased sleepiness or drowsiness during the day. - Irritability: mood changes including agitation or hostility. - Headache: mild to moderate pain in the head, often pressure‑like. - Nausea: sensation of stomach upset that may lead to vomiting. Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema): rapid onset of swelling, hives, or breathing difficulty. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin blistering and detachment. - Suicidal thoughts or behavior: emergence of depressive symptoms or urges to self‑harm, requiring immediate medical attention.

When using Levetiracetam, clinicians should consider several precautionary measures to ensure safe and effective therapy. - Renal impairment: adjust dose based on creatinine clearance. - Hepatic impairment: monitor liver function tests regularly. - Pregnancy: use only if potential benefit justifies potential risk to fetus. - Concomitant CNS depressants: observe for enhanced sedation or respiratory depression. - Behavioral changes: monitor patients for irritability, aggression, or mood swings. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines, influencing its plasma concentration or enhancing pharmacodynamic effects. Major Interactions (Avoid): - Carbamazepine: induces metabolism, markedly reducing levetiracetam levels. - Phenytoin: enzyme induction may lower levetiracetam exposure. - Phenobarbital: can decrease levetiracetam concentrations through hepatic induction. Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): additive sedation risk. - Alcohol: may potentiate central nervous system effects. - Other antiepileptics (e.g., valproate): monitor for combined toxicity.